Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

vTv Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

vTv Therapeutics şirketinin toplam hissedar öz sermayesi $20.4M ve toplam borcu $0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $46.5M ve $26.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

US$0

Borç

Faiz karşılama oranı	n/a
Nakit	US$45.59m
Eşitlik	US$20.44m
Toplam yükümlülükler	US$26.02m
Toplam varlıklar	US$46.46m

Son finansal sağlık güncellemeleri

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

Aug 24

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

May 11

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17

Recent updates

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Aug 17

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Mar 03

vTv Therapeutics inks licensing deal for HPP971, shares up 11%

Dec 15

MacAndrews & Forbes buys 625K shares of vTv Therapeutics

Dec 11

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: VTVT 'nin kısa vadeli varlıkları ( $46.2M ) kısa vadeli yükümlülüklerini ( $7.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: VTVT şirketinin kısa vadeli varlıkları ( $46.2M ) uzun vadeli yükümlülüklerini ( $19.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: VTVT borçsuzdur.

Borcun Azaltılması: VTVT şu anda borcu yok ancak 5 yıl öncesine ait verimiz olmadığı için karşılaştırma yapamıyoruz.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: VTVT şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: VTVT serbest nakit akışı her yıl % { 6.6 1.7 |round(1)}} yıl boyunca yeterli nakit akışına sahip olacaktır.

vTv Therapeutics Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

Recent updates

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

Here's Why We're Watching vTv Therapeutics' (NASDAQ:VTVT) Cash Burn Situation

New major risk - Share price stability

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

New minor risk - Shareholder dilution

vTv Therapeutics Announces Screening of First Patient in CATT1 Pivotal Trial Evaluating Cadisegliatin for Type 1 Diabetes

New minor risk - Shareholder dilution

New minor risk - Shareholder dilution

vTv Therapeutics Inc., Annual General Meeting, Jun 11, 2024

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $12.678712 million.

New minor risk - Shareholder dilution

Less than half of directors are independent

vTv Therapeutics Inc. Announces FDA Submission for First Phase 3 Study of Cadisegliatin in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Board Changes

vTv Therapeutics Inc. has filed a Follow-on Equity Offering in the amount of $4.923802 million.

Vtv Therapeutics Inc. Announces Resignation of Chandresh Harjivan as Member of the Board of Directors

vTv Therapeutics Receives Non-Compliance Notice From Nasdaq

Vtv Therapeutics Inc. Appoints Thomas Strack, M.D., as Chief Medical Officer

New minor risk - Share price stability

New major risk - Negative shareholders equity

First half 2023 earnings released: US$0.12 loss per share (vs US$0.15 loss in 1H 2022)

Nasdaq Approves vTv Therapeutics' Request to Extend the Period to Regain Compliance with the Minimum Bid Requirement Until December 18, 2023

First quarter 2023 earnings released: US$0.055 loss per share (vs US$0.10 loss in 1Q 2022)

vTv Therapeutics Inc. to Report Q1, 2023 Results on May 11, 2023

Will vTv Therapeutics (NASDAQ:VTVT) Spend Its Cash Wisely?

Full year 2022 earnings: EPS exceeds analyst expectations

vTv Therapeutics Inc. Appoints Elizabeth Keiley as Executive Vice President and General Counsel

vTv Therapeutics Receives a Letter from NASDAQ Regarding Minimum Bid Price

vTv Therapeutics Inc. Appoints Steven Tuch as Chief Financial Officer

Independent Director recently bought US$51k worth of stock

Consensus forecasts updated

Consensus forecasts updated

Third quarter 2022 earnings released: US$0.053 loss per share (vs US$0.018 loss in 3Q 2021)

High number of new directors

Consensus revenue estimates increase by 17%

vTv Therapeutics Inc. Appoints Jonathan Isaacsohn as Member and Chair of the Board

Second quarter 2022 earnings released: US$0.045 loss per share (vs US$0.01 loss in 2Q 2021)

vTv Therapeutics GAAP EPS of -$0.04

High number of new directors

vTv Therapeutics Inc. Announces CEO Changes

Jon Isaacsohn to Join the vTv Therapeutics Inc. Board of Directors

vTv stock soars 18% on $10M equity investment by CinRx Pharma

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Publication in Diabetes Obesity and Metabolism of Complete Results for the Mechanistic Study Assessing Effects of TTP399 on Ketones during Acute Insulin Withdrawal in Patients with Type 1 Diabetes

vTv Therapeutics Inc. announced that it expects to receive $24.999762 million in funding from G42 Investments Ai Holding Rsc Ltd

First quarter 2022 earnings released: US$0.10 loss per share (vs US$0.075 loss in 1Q 2021)

vTv Therapeutics Inc., Annual General Meeting, Jun 01, 2022

Price target decreased to US$5.00

Robin E. Abrams Resigns as Executive Chairperson of the Board of Directors of vTv Therapeutics Inc

vTv Therapeutics Inc. Announces Not to Stand for Re-Election of Noel Spiegel as Director and Chair of the Audit Committee of the Board

Price target decreased to US$5.00

Full year 2021 earnings released: US$0.21 loss per share (vs US$0.18 loss in FY 2020)

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Inc. Announces Results of Multiple Ascending Dose Study and Development Plan for HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

We Think vTv Therapeutics (NASDAQ:VTVT) Needs To Drive Business Growth Carefully

vTv Therapeutics Inc.(NasdaqCM:VTVT) dropped from Russell 3000E Index

First quarter 2021 earnings released: US$0.075 loss per share (vs US$0.11 loss in 1Q 2020)

vTv Therapeutics Inc. Announces Initiation of Study Evaluating TTP399’s Potential to Reduce Risk of Diabetic Ketoacidosis in Patients with Type 1 Diabetes

Director recently bought US$172k worth of stock

The Director of vTv Therapeutics Inc. (NASDAQ:VTVT), Richard Nelson, Just Bought A Few More Shares

Full year 2020 earnings released: US$0.18 loss per share (vs US$0.59 loss in FY 2019)

Revenue beats expectations

vTv Therapeutics Announces Publication in Diabetes Care of Results from SimpliciT-1 Study of TTP399 in Patients with Type 1 Diabetes

vTv Therapeutics Inc. Announces Initiation of Multiple Ascending Dose Study of HPP737, an Oral PDE4 Inhibitor for the Treatment of Psoriasis

vTv Therapeutics Inc. Announces Executive Changes

vTv Therapeutics Announces Results of Phase 2 Elevage Study of Azeliragon in Patients with Mild Alzheimer's Disease and Type 2 Diabetes

vTv Therapeutics inks licensing deal for HPP971, shares up 11%